Rakovina Therapeutics Inc (RKV : TSX-V)
Common Stock
$0.14
CAD
+0.01 (3.70%)
Last updated: 2026-06-24
RKV
Rakovina Therapeutics Inc
WealthAwesomePerformance
1 Day
+3.70%
1 Week
+3.70%
1 Month
+0.00%
YTD
+40.00%
Key Statistics
Market Cap
$3.30M
52W High
$0.84
52W Low
$0.09
P/E Ratio
-
50 Day MA
$0.13
200 Day MA
$0.16
Beta
-0.22
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/24/2026 | $0.14 | $0.14 | $0.14 | $0.14 | $0.14 | 1,005 |
| 6/23/2026 | $0.14 | $0.14 | $0.14 | $0.14 | $0.14 | 0 |
| 6/22/2026 | $0.14 | $0.14 | $0.14 | $0.14 | $0.14 | 6,557 |
| 6/19/2026 | $0.14 | $0.15 | $0.14 | $0.15 | $0.15 | 39,566 |
| 6/18/2026 | $0.14 | $0.14 | $0.14 | $0.14 | $0.14 | 36,021 |
| 6/17/2026 | $0.14 | $0.14 | $0.14 | $0.14 | $0.14 | 20,720 |
| 6/16/2026 | $0.14 | $0.14 | $0.14 | $0.14 | $0.14 | 0 |
| 6/15/2026 | $0.14 | $0.14 | $0.14 | $0.14 | $0.14 | 25,020 |
| 6/12/2026 | $0.14 | $0.14 | $0.14 | $0.14 | $0.14 | 41,000 |
| 6/11/2026 | $0.14 | $0.14 | $0.14 | $0.14 | $0.14 | 8,500 |
Analyst Price Targets
Based on analyst covering RKV
Wall Street analysts forecast RKV stock price to rise 2757.1% over the next 12 months.
Consensus
No RatingAvg. Target
C$4.00
+2757.1% Upside
Current Price
C$0.14
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RKV's historical volatility
30-Day Vol
128.6%
Annualized
90-Day Vol
149.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.17
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.15 | C$0.10 โ C$0.23 |
| 60 trading days | C$0.16 | C$0.08 โ C$0.30 |
| 90 trading days | C$0.17 | C$0.08 โ C$0.36 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor cells. The company is also involved in the development of kt-5000 series of brain-penetrant dual ATR"mTOR inhibitor drug candidates. It has a strategic collaboration with Variational AI Inc. to develop AI-generated ATR inhibitor compounds; and a non-binding Letter of Intent to form a joint venture to co-develop AI-discovered small-molecule oncology therapies. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-7.11M
- Profit Margin
- 0.00%
- ROE (TTM)
- -891.37%
- EPS (Diluted)
- -0.41
- Book Value
- 0.09
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About RKV
Articles Featuring RKV.V
Latest articles and analysis covering RKV.V
